HBS-301 Tablet Phase 3 for Idiopathic Hypersomnia

ClinicalTrials.gov has published a new trial registration for HBS-301 tablets, a Phase 3 investigational treatment for idiopathic hypersomnia (NCT07500090). The registry entry documents trial identification, phase classification, therapeutic indication, and recruitment status. No new regulatory requirements, reporting obligations, or compliance deadlines are established by this posting.

Pharmaceutical companies and clinical investigators should update internal clinical trial management systems to reflect this new Phase 3 study. Healthcare providers treating idiopathic hypersomnia patients may use this registry to identify trial access opportunities for eligible patients. This is a routine registry posting; no immediate regulatory action or deadline is triggered.